Janux Therapeutics
Market cap $655M 61.2M shares (10-Q, Nov 3, 2026) × $10.71 close Nov 17, 2026
Most recent annual filing: 2026-02-26
- JANX007 readout1H 2027JANX007 readout, 1H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
JANX011
- Undisclosed indication
JANX013
JANX014
Technology platforms
TRACTr
Tumor Activated T Cell Engager platform — bispecific molecules with tumor antigen-binding domain and CD3 T cell binding domain, with tumor-protease-cleavable peptide masks and albumin-binding domain for extended half-life; focus on solid tumors in oncology
Targets: CD3, PSMA
TRACIr
Tumor Activated Immunomodulator platform — bispecific molecules with tumor antigen-binding domain and costimulatory CD28 binding domain; designed to enhance T cell activation and durability; focus on solid tumors in oncology
Targets: CD28, PSMA
ARM
Adaptive Immune Response Modulator platform — redesigned bispecific T cell engagers targeting B cells via CD19 for rapid, deep and durable B-cell depletion with memory B-cell reset; off-the-shelf, subcutaneous, re-dosable format; focus on autoimmune diseases and oncology
Targets: CD19, CD3, TRBV6
TRACTr · Bristol Myers Squibb
Tumor Activated T Cell Engager platform; focus areas include prostate cancer and other solid tumors
Targets: PSMA
TRACTr · Merck
Tumor Activated T Cell Engager platform — proprietary immunotherapy technology producing novel T cell engager candidates for cancer treatment
Discontinued (1)
- JANX008 — undisclosed · strategic deprioritization following completion of Phase 1a
Capital (as filed)
- Cash
- $41.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $904M Sep 30, 2026
- Operating cash flow
- −$25.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $946M cash per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-10 UPDATE: Janux Therapeutics (JANX) - The “Positive” Data Crash ★ Distilled Pro
- 2026-11-06 UPDATE: Janux Therapeutics (JANX) - The Clock is Set 🔒 Paid
- 2026-09-15 UPDATE: Janux Therapeutics (JANX) - The CD28 Card Gets Played 🔒 Paid
- 2026-08-07 UPDATE: Janux Therapeutics (JANX) - The Quiet Quarter With a Loud R&D Line 🔒 Paid
- 2026-06-23 UPDATE: Janux Therapeutics (JANX) - The CMO Walks After Six Months 🔒 Paid
- 2026-05-09 UPDATE: Janux Therapeutics (JANX) - The BMS Milestone Hits, the Catalyst Slips 🔒 Paid
- 2026-04-29 Janux Pharmaceuticals (JANX) - Scientific Deep Dive for JANX007 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Janux Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-29 Buy core Janux Pharmaceuticals (JANX) - Scientific Deep Dive for JANX007 and Pipeline Products JANX007 shows compelling clinical data with a clean safety profile, the fortress balance sheet eliminates dilution risk, and BMS partnership validates the TRACTr platform, despite WuXi Biologics supply chain risk and JANX008 discontinuation.
- 2026-05-09 Buy core UPDATE: Janux Therapeutics (JANX) - The BMS Milestone Hits, the Catalyst Slips BMS $35M development candidate milestone validates the platform, fortress balance sheet intact, and JANX007 thesis unchanged despite the data readout slipping to 1H 2027.
- 2026-06-23 Buy core UPDATE: Janux Therapeutics (JANX) - The CMO Walks After Six Months CMO departure is a yellow flag but not thesis-breaking; JANX007 data and BMS validation are unchanged, and the fortress balance sheet covers a CMO search and full 2026-2027 readout slate.
- 2026-08-07 Buy core UPDATE: Janux Therapeutics (JANX) - The Quiet Quarter With a Loud R&D Line All timelines held under leadership transition, fortress grew to $970.9M, BMS validation compounding, and JANX011 spend drop is a watch item not a red flag.
- 2026-09-15 Buy core UPDATE: Janux Therapeutics (JANX) - The CD28 Card Gets Played JANX013 dosed first patient on schedule under interim leadership, franchise moat now three-deep in the clinic, and JANX007 crown jewel thesis intact ahead of 1H 2027 congress update.
- 2026-11-06 Hold UPDATE: Janux Therapeutics (JANX) - The Clock is Set All 2H 2026 commitments met or dated, fortress intact, but existing holders should hold through the JANX011 readout while new money should wait four days for the data rather than chase the pre-event discount.
- 2026-11-10 Buy core UPDATE: Janux Therapeutics (JANX) - The "Positive" Data Crash JANX011 cleared the cytokine safety test but missed on depletion depth and added a liver signal, downgrading the autoimmune option to show-me; the core JANX007 thesis and fortress balance sheet are untouched, and the post-crash drop represents the kind of weakness the original verdict flagged as a buy opportunity.
- Long call · opened Apr 29, 2026 at $14.11 · -24.1% vs XBI +12.7% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Initial clinical data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026.”
matched to JANX011 · interim data
-
-
-
“Initial clinical data from the Phase 1 healthy volunteer study of JANX011 expected to be announced in the second half of 2026.”
matched to JANX011 · interim data -
“In addition, we are developing JANX013, a PSMA-targeted TRACIr incorporating CD28 costimulation, which is planned to enter clinical development in the second half of 2026.”
matched to JANX013 · trial initiation
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (17)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseJanux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease→ BD updateThe JANX011 autoimmune lottery ticket hit: >90% B-cell depletion, Grade 1-only CRS, zero SAEs across 25 healthy volunteers — yet JANX closed down 27.6% on the day. The data said yes; the market said sell.
- Nov 5, 2026ReleaseJanux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateFour days before Janux presents the first clinical data from the ARM platform (JANX011), the Q3 release drops a new mechanism disclosure: the drug selectively engages a specific T cell subset (TRBV6-expressing) rather than broad CD3+ activation — a detail that completely reframes what readers should be watching for on November 9.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseJanux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
- Sep 14, 2026ReleaseJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013→ BD updateJANX013 — the CD28 co-stimulatory "Signal 2" franchise protector I've been tracking — just dosed its first patient, on schedule, in combination with JANX007. The clinical org is executing through the CMO vacancy; the PSMA moat is widening.BD extracted 1 program update from this document → JANX pipeline
- Aug 6, 2026ReleaseJanux Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsBD extracted 1 program update from this document → JANX pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jun 23, 20268-KCurrent report: other events
- Jun 12, 20268-KCurrent report: shareholder vote
- May 7, 2026ReleaseJanux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Apr 28, 20268-KCurrent report: officer / director change
10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Jul 28, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 12, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 6, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 28, 2026ARSAnnual report to shareholders